EP3936113A1 - Microsphères dégradables hydrophiles pour administration de travoprost - Google Patents

Microsphères dégradables hydrophiles pour administration de travoprost Download PDF

Info

Publication number
EP3936113A1
EP3936113A1 EP20305777.3A EP20305777A EP3936113A1 EP 3936113 A1 EP3936113 A1 EP 3936113A1 EP 20305777 A EP20305777 A EP 20305777A EP 3936113 A1 EP3936113 A1 EP 3936113A1
Authority
EP
European Patent Office
Prior art keywords
travoprost
composition
advantageously
hydrophilic
degradable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP20305777.3A
Other languages
German (de)
English (en)
Inventor
Anne BEILVERT
Emeline CORUS
Laurent Bedouet
Laurence Moine
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
OCCLUGEL
Original Assignee
OCCLUGEL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by OCCLUGEL filed Critical OCCLUGEL
Priority to EP20305777.3A priority Critical patent/EP3936113A1/fr
Priority to US18/003,180 priority patent/US20230241017A1/en
Priority to JP2023525117A priority patent/JP2023533391A/ja
Priority to PCT/EP2021/068911 priority patent/WO2022008625A1/fr
Priority to AU2021304877A priority patent/AU2021304877A1/en
Priority to EP21742107.2A priority patent/EP4178533A1/fr
Publication of EP3936113A1 publication Critical patent/EP3936113A1/fr
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals

Definitions

  • the present invention relates to hydrophilic degradable microsphere for delivering a prostaglandin analogue.
  • the present invention relates to composition comprising an effective amount of prostaglandin analogues and hydrophilic degradable microspheres.
  • the present invention also relates to said composition for use for preventing and/or treating ocular hypertension or glaucoma.
  • Glaucoma is a disease that damages the eye's optic nerve leading to progressive, irreversible vision loss. Glaucoma usually happens when fluid builds up in the front part of the eye. That extra fluid increases the pressure in the eye, inducing cell death of retinal ganglion cell neurons and their axons damaging the optic nerve over time. The damages created are irreversible, glaucoma is the second cause of blindness in the world. Actually around 60 million people are affected worldwide while 100 million are forecast in 2040 ( Yadav 2019, Materials Science ⁇ t Engineering C : 103 ). The economic burden of glaucoma is important, with an overall cost to Medicare of $748 million in 2009 ( Lambert 2015, Transl Vis Sci Technol. 4(1 )). Annual eye care-related costs for glaucoma patients with no vision loss were $8157 (2007 US dollars); this increased to $14,237 for moderate to severe vision loss before reaching $18,670 for patients blinded by the disease.
  • the two main types of glaucoma are primary open-angle glaucoma and angle-closure glaucoma.
  • Primary open-angle glaucoma is the most common form of the disease. The drainage angle formed by the cornea and iris remains open, but the trabecular meshwork is partially blocked. This leads to a gradual increase in pressure in the eye. This pressure damages the optic nerve and may lead to vision loss without signs or symptoms.
  • Angle-closure glaucoma also called closed-angle glaucoma, occurs when the iris swells forward to narrow or block the drainage angle formed by the cornea and iris. As a result, fluid cannot circulate through the eye and pressure increases.
  • Angle-closure glaucoma may occur suddenly (acute angle-closure glaucoma) or gradually (chronic angle-closure glaucoma). If treated early, the progression of glaucoma can be slowed or stopped with medication, laser treatment, or surgery. The goal of these treatments is to reduce intraocular pressure, since it is impossible to repair the optic nerve. Eye drops are the treatment of choice for primary open-angle glaucoma. Treatments are therefore aimed to increase the elimination of aqueous humor, decrease its production or both.
  • Reduction of aqueous humor production is the therapeutic goal achieved with carbonic anhydrase inhibitors (Brinzolamide, Dorzolamide) and ⁇ -blockers (Timolol, Levobunolol, Betaxolol, Carteolol).
  • Other medications accelerate its elimination such as prostaglandin analogues (latanoprost, Bimatoprost travoprost).
  • Subconjunctival injection in humans is a safe technique commonly used for various indications: injection of mitomycin C to decrease intraocular pressure ( Gandolfi et al; 1995. Arch Ophthalmol. 113:582-5 ), corticosteroid injection for the treatment of anterior scleritis ( Sen et al; 2005. Br J Ophthalmol. 89: 917-8 ) or macular oedema ( Carbon Craig et al; 2017. J Fr Ophtalmol. 40:177-86 ).
  • the conjunctiva covers the anterior sclera, the bulbar conjunctiva, and lines the inner side of the eyelids, the palpebral conjunctiva.
  • the conjunctiva is a thin, transparent membrane composed of an epithelium and stroma layers.
  • the average total thickness of the human bulbar conjunctiva is around 240 ⁇ m, with an epithelium thickness of ⁇ 50 ⁇ m and a stroma thickness of ⁇ 190 ⁇ m ( Zhang et al; 2011. Invest Ophthalmol Vis Sci. 52:7787-91 ).
  • the subconjunctival injections occurred between the bulbar conjunctiva and the sclera.
  • the injected volumes are usually between 0.1 and 0.5 mL ( Subrizi et al; 2019, Drug Discovery Today, 24: 1446-57 ).
  • compositions were investigated for sustained drug delivery after single subconjunctival injection. Their delivery performances were evaluated in vitro and in vivo in rabbit or monkey.
  • DDS were prepared with timolol maleate (a beta-blocker). Timolol maleate was incorporated in microfilm implants (4 x 6 mm) with a thickness of 40 ⁇ m made of a copolymer of poly(lactide-co-caprolactone). Then, in monkeys after a limited conjunctival dissection, one timolol loaded microfilm was inserted before suture of the conjunctiva. A sustained intraocular pressure (IOP) reduction was observed for 5 months ( Ng et al; 2015. Drug Deliv. and Transl. Res.
  • IOP intraocular pressure
  • brimonidine tartrate was incorporated in PLGA microspheres (average diameter of 7.4 ⁇ m).
  • PLGA microspheres average diameter of 7.4 ⁇ m.
  • Brinzolamide a carbonic anhydrase inhibitor which decreases the secretion of aqueous humor, was encapsulated in nanoparticles of PLGA.
  • Their subconjunctival injection in normotensive rabbits triggers a reduction for 10 days ( Salama et al; 2017. AAPS PharmSciTech. 18 : 2517-28 ).
  • Injectable DDS for sustained delivery of prostaglandin analogues for subconjunctival injections were described.
  • Giarmoukakis et al (Exp Eye Res. 112:29-36; 2013 ) reported preparation of PLA-PEG nanoparticles (80 nm size) containing latanoprost. In vitro, the release was achieved after one week, and in vivo after minimally invasive subconjunctival injection, a significant hypotensive effect for up to 8 days was obtained in normotensive rabbit.
  • Latanoprost was also encapsulated in liposomes of 100 nm.
  • DDS degradable microfilms, microspheres, liposomes or nanoparticles
  • This route of administration of hypotensive drug incorporated in DSS seems efficient.
  • Some of the DDS described above are inappropriate for clinical use, such the solid implants of PLGA which require an incision of conjunctiva for their implantation.
  • the others DDS liposomes, nanospheres, microspheres
  • DDS containing the anti-glaucoma drugs appears to be key parameters. Ideally, their size should be larger than the diameter of the blood vessels in the conjunctival tissue, but they should be flexible enough to be injected through thin needles.
  • the inventors surprisingly found strong interaction between prostaglandin analogues such as travoprost with hydrophilic degradable microspheres of size range 50-100 ⁇ m composed of a crosslinked hydrogel.
  • Prostaglandin analogues are a class of drugs that bind to a prostaglandin receptor. Prostaglandin analogues are used for the treatment of most forms of glaucoma. The compounds should be used whenever low target pressures are called for in both normal-tension glaucoma or primary open-angle glaucoma (POAG), as well as ocular hypertensive (OHT) patients where treatment seems mandatory.
  • POAG primary open-angle glaucoma
  • OHT ocular hypertensive
  • the most commonly known prostaglandin analogues are travoprost, latanoprost, bimatoprost and tafluprost.
  • Travoprost a prostaglandin analogue
  • Travoprost is used to treat open angle glaucoma when other agents are not sufficient.
  • Travoprost is a synthetic analogue of prostaglandin F2 ⁇ that works by increasing the outflow of aqueous fluid from the eyes.
  • Travoprost concentration of eye drops solutions is 40 ⁇ g/mL, and according to a dosage of 1 drop ( ⁇ 50 ⁇ L) in the conjunctival sac of the eye once a day, approximatively 2 ⁇ g of travoprost are applied to the cornea every day.
  • a local DDS of travoprost must be able to release this amount every day for several months.
  • the present invention offers the possibility to tune the amount of loaded prostaglandin analogues such as travoprost (25-50-fold higher than commercial topical travoprost) and the flow rate of prostaglandin analogues such as travoprost release during the time.
  • the relatively large diameter of the microsphere compared to the anterior art would minimize the retrograde occlusion danger of the retina and of the choroidal vessels during the subconjunctival injection.
  • hydrophilic degradable microspheres that may be used as biocompatible drug carrier for peri-ocular drug delivery and that present affinity with the active ingredient prostaglandin analogues such as travoprost, latanoprost, bimatoprost and tafluprost, in particular travoprost.
  • the inventors have thus discovered a prostaglandin analogues delivery system that is free of organic solvent, that presents a tuneable degradation time from day to months, that is easy to load (in water, at room temperature), that allows a long-term drug release and that avoids intense inflammatory reaction.
  • the invention relates to a composition
  • a composition comprising an effective amount of a prostaglandin analogue, at least one hydrophilic degradable microsphere comprising a crosslinked matrix, and a pharmaceutically acceptable carrier for administration by injection, the crosslinked matrix being based on at least:
  • the invention in a second aspect, relates to the composition of the invention, for use for preventing and/or treating ocular hypertension or glaucoma.
  • the invention relates to the hydrophilic degradable microsphere of the invention for use for delivering an effective amount of a prostaglandin analogue, advantageously of travoprost, to a subject in need thereof.
  • the invention relates to a pharmaceutical kit comprising:
  • matrix based on a matrix comprising the mixture and/or the product of the reaction between the starting components used for the heterogeneous medium polymerisation of this matrix, preferably only the product of the reaction between the different starting components used for this matrix, some of which may be intended to react or may react with each other or with their close chemical environment, at least in part, during the different phases of the process of manufacture of the matrix, in particular during a polymerisation stage.
  • the starting components are the reagents intended to react together during the polymerization of the matrix.
  • the starting components are therefore introduced into a reaction mixture optionally additionally comprising a solvent or a mixture of solvents and/or other additives such as at least one salt and/or at least one polymerization initiator and/or at least one stabilizer such as PVA.
  • the reaction mixture comprises at least the monomers a), b), c) as defined in the claims and in this description, optionally a polymerization initiator such as, for example, t-butyl peroxide, benzoyl peroxide, azobiscyanovaleric acid (also called 4,4'-Azobis(4-cyanopentanoic acid)), AIBN (azobisisobutyronitrile), or 1,1'- Azobis(cyclohexane carbonitrile) or one or more photo-initiators such as 2-Hydroxy-4'-(2-hydroxyethoxy)-2-methylpropiophenone (106797-53-9); 2-Hydroxy-2-methylpropiophenone (Daroc
  • organic phase of the reaction mixture means the phase comprising the organic solvent and the compounds soluble in said organic solvent, in particular the monomers, and the polymerization initiator.
  • (C X -C Y )alkyl group mean a saturated monovalent hydrocarbon chain, linear or branched, containing X to Y carbon atoms, X and Y being integers between 1 and 36, preferably between 1 and 18, in particular between 1 and 6. Examples are methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl, pentyl or hexyl groups.
  • aryl group and "(C X -C Y )aryl” mean an aromatic hydrocarbon group, preferably having X to Y carbon atoms, and comprising one or more adjacent rings, X and Y being integers between 5 and 36, preferably between 5 and 18, in particular between 5 and 10. Examples are phenyl or naphthyl groups.
  • partition coefficient P mean the ratio of concentrations of a compound in a mixture of two immiscible solvents at equilibrium: water and 1-octanol. This ratio is therefore a comparison of the solubilities of the solute in these two liquids.
  • the octanol/water partition coefficient measures how hydrophilic (octanol/water ratio ⁇ 1) or hydrophobic (octanol/water > 1) a compound is.
  • Partition coefficient P may be determined by measuring the solubilities of the compound in water and in 1-octanol and by calculating the ratio solubility in octanol / solubility in water. Partition P may also be determined in silico.
  • R N CHlactide + N CH 3 lactide + N CH 2 glycolide + 5 ⁇ N CH 2 caprolactone N EO unit with N being an integer and representing the number of unit(s).
  • the terms "degradable microsphere” mean that the microsphere is degraded or cleaved by hydrolysis in a mixture of degradation products composed of low-molecular-weight compounds and water-soluble polymer chains having molecular weights below the threshold for renal filtration of 50 kg mol -1 . Compared to non-degradable microspheres, no ester hydrolysable bonds is present within the crosslinker.
  • the expression "between X and Y" means a range of numerical values in which the limits X and Y are inclusive.
  • immediate release (IR) of an active ingredient means the rapid release of the active ingredient from the formulation to the location of delivery as soon as the formulation is administered.
  • the expression "extended-release” of an active ingredient means either the “sustained-release (SR)” or the “controlled-release (CR)” of active ingredients from the formulation to the location of delivery at a predetermined rate for an extended period of time and maintaining a constant active ingredient level for this period of time with minimum side effects.
  • the controlled-release (CR) differs from the sustained-release (SR) in that CR maintains drug release over a sustained period at a constant rate whereas SR maintains drug release over a sustained period but not at a constant rate.
  • sustained-release of an active ingredients means an extended-release (as defined above) of an active ingredient from the formulation to the location of delivery in order to maintain for a certain predetermined time the drug in tissue of interest at therapeutic concentrations by means of an initial dose portion.
  • controlled-release (CR) of an active ingredient means an extended-release (as defined above) of an active ingredient from the formulation to the location of delivery, that provides some control of temporal or spatial nature, or both.
  • the term “pharmaceutically acceptable” is intended to mean what is useful to the preparation of a pharmaceutical composition, and what is generally safe and non toxic, for a pharmaceutical use.
  • pharmaceutically acceptable salt » is intended to mean, in the framework of the present invention, a salt of a compound which is pharmaceutically acceptable, as defined above, and which possesses the pharmacological activity of the corresponding compound.
  • Such salts comprise:
  • the hydrophilic degradable microsphere comprises a crosslinked matrix that is based on at least:
  • the components a) the hydrophilic monomer of general formula (I), b) the cyclic monomer having an exo-methylene group of formula (II), and c) the degradable block copolymer cross-linker, are thus starting components of the crosslinked matrix.
  • the hydrophilic degradable microsphere is a swellable degradable (i.e. hydrolyzable) cross-linked polymer in the form of spherical particle having a diameter after swelling ranging between 20 ⁇ m and 1200 ⁇ m.
  • the polymer of the invention is constituted of at least one chain of polymerized monomers a), b) and c) as defined above.
  • a polymer is swellable if it has the capacity to absorb liquids, in particular water.
  • size after swelling means thus that the size of the microspheres is considered after the polymerization and sterilization steps that take place during their preparation.
  • the microsphere of the invention has a diameter after swelling of between 20 ⁇ m and 100 ⁇ m, 40 ⁇ m and 150 ⁇ m, 100 ⁇ m and 300 ⁇ m, 300 ⁇ m and 500 ⁇ m, 500 ⁇ m and 700 ⁇ m, 700 ⁇ m and 900 ⁇ m or 900 ⁇ m and 1200 ⁇ m, advantageously of between 20 ⁇ m and 100 ⁇ m, 40 ⁇ m and 150 ⁇ m, 100 ⁇ m and 300 ⁇ m, 300 ⁇ m and 500 ⁇ m, 500 ⁇ m and 700 ⁇ m as determined by optical microscopy.
  • Microspheres are advantageously small enough in diameter to be injected through needles, catheters or microcatheters with internal diameters ranging from a few hundred micrometres to more than one millimetres.
  • hydrophilic monomer mean a monomer having a high affinity for water, i.e. tending to dissolve in water, to mix with water, to be wetted by water, or capable of swelling in water after polymerization.
  • the hydrophilic monomer a) is selected from the group consisting of sec-butyl acrylate, n-butyl acrylate, t-butyl acrylate, t-butyl methacrylate, methylmethacrylate, N-dimethylaminoethyl(methyl)acrylate, N,N-dimethylaminopropyl-(meth)acrylate, t-butylaminoethyl (methyl)acrylate, N,N-diethylaminoacrylate, acrylate terminated poly(ethylene oxide), methacrylate terminated poly(ethylene oxide), methoxy poly(ethylene oxide) methacrylate, butoxy poly(ethylene oxide) methacrylate, acrylate terminated poly(ethylene glycol), methacrylate terminated poly(ethylene glycol), methoxy poly(ethylene glycol) methacrylate, butoxy poly(ethylene glycol) methacrylate; advantageously acrylate terminated poly(ethylene glycol), methacrylate terminated poly(ethylene glycol
  • the hydrophilic monomer a) is poly(ethylene glycol) methyl ether methacrylate.
  • the hydrophilic monomer a) is advantageously present in the reaction mixture in an amount of between 10% and 90%, preferably from between 30% and 80 % by mole, relative to the total number of moles of the monomers.
  • component b) is a cyclic monomer having an exo-methylene group of formula (II) as defined above, wherein:
  • component b) is a cyclic monomer having an exo-methylene group of formula (II) as defined above, wherein:
  • component b) is a cyclic monomer having an exo-methylene group of formula (II) as defined above, wherein:
  • the component b) is selected from the group consisting of 2-methylene-1,3-dioxolane, 2-methylene-1,3-dioxane, 2-methylene-1,3-dioxepane, 2-Methylene-1,3,6-Trioxocane and derivatives thereof, in particular benzo derivatives and phenyl substituted derivatives, advantageously from the group consisting of 2-methylene-1,3-dioxolane, 2-methylene-1,3-dioxane, 2-methylene-1,3-dioxepane, 2-methylene-4-phenyl-1,3-dioxolane, 2-Methylene-1,3,6-Trioxocane and 5,6-benzo-2-methylene-1,3dioxepane, more advantageously from the group consisting of 2-methylene-1,3-dioxepane, 5,6-benzo-2-methylene-1,3dioxepane and 2-Methylene-1,3,6-Trioxo
  • the cyclic monomer b) having an exo-methylene group of general formula (II) is advantageously present in the reaction mixture in an amount of between 0.1 % and 30 %mol, preferably from between 1% and 20 %, and in particular between 1% and 10% by mole, relative to the total number of moles of the monomers.
  • the degradable block copolymer crosslinker has a partition coefficient P of between 0.50 and 11.20, advantageously between 3.00 and 9.00.
  • the degradable block copolymer crosslinker has a hydrophobic/hydrophilic balance R between 1 and 20, advantageously between 3 and 15.
  • copolymer cross-linker is intended to mean that the copolymer contains a functional group containing a double bond at least two of its extremities in order to link together several polymer chains.
  • the R 11 are identical and are H or a (C 1 -C 6 )alkyl group.
  • the R 11 are identical and are H or a (C 1 -C 6 )alkyl group.
  • n may be identical or different in each arm of the PEG.
  • the crosslinker c) is of general formula (IIIa), (IIIb) or (IIIc), in particular (IIIa) or (IIIb), as defined above, wherein X represents PLAPCL or PCL. More advantageously, the crosslinker c) is of general formula (IIIa), (IIIb) or (IIIc), in particular (IIIa) or (IIIb), wherein X represents PCL.
  • the crosslinker c) is of general formula (IIIa), (IIIb) or (IIIc), in particular (IIIa) or (IIIb), as defined above, wherein n and k independently being integers from 1 to 150, and p being an integer from 1 to 100.
  • the crosslinker c) is of general formula (IIIa), (IIIb) or (IIIc), in particular (IIIa) or (IIIb), as defined above, wherein the R 11 are identical and are H or a (C 1 -C 6 )alkyl group.
  • crosslinker c) is selected from the group consisting of compounds of general formula (IIIa), (IIIb) or (IIIc), in particular (IIIa) or (IIIb), as defined above, wherein:
  • the polyethylene glycol (PEG) has a length of 100 to 10 000 g/mol, preferably 100 to 2 000 g/mol, more preferably 100 to 1 000 g/mol.
  • the crosslinker c) is advantageously present in the reaction mixture in an amount of between 5 % and 90 %mol, preferably from between 5% and 60 % by mole, more preferably between 15 % and 60 % by mole, relative to the total number of moles of the monomers.
  • Increasing the amount of crosslinker, and thus decreasing the mesh size of the resulting microsphere influences the loading of the microsphere in prostaglandin analogues, such as travoprost, and then the release of the prostaglandin analogues, such as travoprost.
  • an optimal release of the travoprost is achieved, in particular because it prevents the immediate release of a large part of the travoprost.
  • the crosslinked matrix of the hydrophilic degradable microsphere is advantageously further based on a chain transfer agent d).
  • transfer agent means a chemical compound having at least one weak chemical bond. This agent reacts with the radical site of a growing polymer chain and interrupts the growth of the chain. In the chain transfer process, the radical is temporarily transferred to the transfer agent which restarts growth by transferring the radical to another polymer or monomer.
  • the chain transfer agent d) is selected from the group consisting of monofunctional or polyfunctional thiols, alkyl halides, transition metal salts or complexes and other compounds known to be active in free radical chain transfer processes such as 2,4-diphenyl-4-methyl-1-pentene. More advantageously, the chain transfer agent is a cycloaliphatic or aliphatic, thiol preferably having from 2 to 24 carbon atoms, more preferably between 2 and 12 carbon atoms, and having or not a further functional group selected from the groups amino, hydroxy and carboxy.
  • the chain transfer agent d) is selected from the group consisting of thioglycolic acid, 2-mercaptoethanol, dodecane thiol and hexane thiol.
  • the chain transfer agent is advantageously present in the reaction mixture in an amount of, for example, from 0.1 to 10%, preferably from 2 to 5 % by mole, relative to the number of moles of monomer a).
  • the crosslinked matrix is only based on starting components a), b), c) and optionally d), as defined above and in the contents abovementioned, no other starting component are thus added to the reaction medium. It is thus clear that the sum of the above-mentioned contents of monomers (a), (b) and (c) must be equal to 100 %.
  • an ionised or ionisable group is understood to be a group which is charged or which may be in charged form (in the form of an ion), i.e. which carries at least one positive or negative charge, depending on the pH of the medium.
  • the COOH group may be ionised in the COO - form
  • the NH 2 group may be ionised in the form of NH 3 + .
  • an ionised or ionisable monomer into the reaction media makes it possible to increase the hydrophilicity of the resulting microspheres, thereby increasing the swelling rate of said microspheres, further facilitating their injection via catheters and microcatheters.
  • the presence of an ionised or ionisable monomer improves the loading of active substances into the microsphere.
  • the ionised or ionisable monomer e) is a cationic monomer, advantageously selected from the group consisting of -(methacryloyloxy)ethyl phosphorylcholine, 2-(dimethylamino)ethyl (meth)acrylate, 2-(diethylamino)ethyl (meth)acrylate and 2-((meth)acryloyloxy)ethyl] trimethylammonium chloride, more advantageously the cationic monomer is diethylamino)ethyl (meth)acrylate.
  • the ionised or ionisable monomer e) is present in the reaction mixture in an amount of between 0 % and 30 % by mole, advantageously between 1 % and 30 % by mole, preferably from between 10% and 15 % by mole, relative to the total number of moles of the monomers.
  • the ionised or ionisable monomer e) is an anionic monomer advantageously selected from the group consisting of acrylic acid, methacrylic acid, 2-carboxyethyl acrylate, 2-carboxyethyl acrylate oligomers, 3-sulfopropyl (meth)acrylate potassium salt and 2-(methacryloyloxy)ethyl]dimethyl-(3-sulfopropyl)ammonium hydroxide, more advantageously, the anionic monomer is acrylic acid.
  • the ionised or ionisable monomer e) is present in the reaction mixture in an amount of between 0 % and 30 % by mole, advantageously between 1 % and 30 % by mole, preferably from between 10% and 15 % by mole, relative to the total number of moles of the monomers.
  • the ionised or ionisable monomer e) is acrylic acid and is advantageously present in the reaction mixture in an amount of between 0 % and 30 % by mole, advantageously between 1 % and 30 % by mole, preferably from between 10% and 15 % by mole, relative to the total number of moles of the monomers.
  • microsphere of the invention can be readily synthesized by numerous methods well-known to the one skilled in the art.
  • the microsphere of the invention can be obtained by direct or inverse suspension polymerization as described below and in the Examples or by microfluidic.
  • a direct suspension may proceed as follows:
  • the surfactant may be selected from the group consisting of hydroxyethylcellulose, polyvinyl alcohol (PVA), polyvinylpyrrolidone, polyethylene oxide, polyethylene glycol and Polysorbate 20 (Tween ® 20).
  • An inverse suspension may proceed as follows:
  • the surfactant may be selected from the group consisting of sorbitan esters such as sorbitan monolaurate (Span ® 20), sorbitan monopalmitate (Span ® 40), sorbitan monooleate (Span ® 80), and sorbitan trioleate (Span ® 85), hydroxyethyl cellulose, mixture of glyceryl stearate and PEG stearate (Arlacel ® ) and cellulose acetate.
  • sorbitan esters such as sorbitan monolaurate (Span ® 20), sorbitan monopalmitate (Span ® 40), sorbitan monooleate (Span ® 80), and sorbitan trioleate (Span ® 85)
  • hydroxyethyl cellulose mixture of glyceryl stearate and PEG stearate (Arlacel ® ) and cellulose acetate.
  • the polymerization initiator may include t-butyl peroxide, benzoyl peroxide, azobiscyanovaleric acid (also known as 4,4'-Azobis(4-cyanopentanoic acid)), AIBN (azobisisobutyronitrile), or 1,1' Azobis (cyclohexane carbonitrile) or one or more photo-initiators such as 2-Hydroxy-4'-(2-hydroxyethoxy)-2-methylpropiophenone (106797-53-9); 2-Hydroxy-2-methylpropiophenone (Darocure 1173, 7473-98-5); 2,2-Dimethoxy-2-phenylacetophenone (24650-42-8); 2,2-dimethoxy-2-phenyl acetophenone (Irgacure ® , 24650-42-8) or 2-Methyl-4'-(methylthio)-2-morpholinopropiophenone (Irgacure ® ,
  • Travoprost loading may proceed by numerous methods well-known to one of skill in the art such as passive adsorption (swelling of the polymer into a drug solution).
  • passive adsorption swelling of the polymer into a drug solution.
  • a concept consists to introduce certain chemical moieties into the polymer backbone that are capable of interacting with the drug via non covalent interactions. Examples of such interactions include electrostatic interactions (described above), hydrophobic interactions, ⁇ - ⁇ stacking, and hydrogen bonding, among others.
  • the composition comprises an effective amount of a prostaglandin analogue such as travoprost, latanoprost, bimatoprost and tafluprost, in particular travoprost.
  • a prostaglandin analogue such as travoprost, latanoprost, bimatoprost and tafluprost, in particular travoprost.
  • the prostaglandin analogue is selected form travoprost, latanoprost, bimatoprost and tafluprost.
  • the prostaglandin analogue is travoprost.
  • the prostaglandin analogues in particular travoprost, is loaded/absorbed onto the microsphere as defined above by non-covalent interactions.
  • This particular way of entrapping drugs or prodrugs is called physical entrapment.
  • Loading of a prostaglandin analogue, in particular travoprost, onto the microsphere of the invention may be proceeded by numerous methods well-known to the one skilled in the art such as preloading a prostaglandin analogue, in particular travoprost, after the microsphere synthesis.
  • composition of the invention comprises between 1 and 6 mg/ml of a prostaglandin analogue, in particular travoprost, more advantageously between 2 and 4 mg/ml.
  • the composition of the invention releases the prostaglandin analogue, in particular the travoprost, without a burst, less 10 % during the first day, followed by a constant delivery rate between 1 % and 5 % of initial loading every day.
  • the composition of the invention releases the prostaglandin analogue, in particular the travoprost, in lachrymal fluid without a burst during the first hour following subconjunctival implantation.
  • Concentration of the prostaglandin analogue, in particular travoprost could remain in the therapeutic range in aqueous humor for 1 to 7 days, advantageously for 1 to 30 days, preferably for 1 to 90 days, the therapeutic range being between 2 ng/ml to 3 ng/ml ( Martinez-de-la-Casa et al; 2012. Eye. 26: 972-75 ) or preferably with low plasma concentration, in the same range as observed after topical treatment ( ⁇ 25 pg/mL) with eye-drops.
  • the composition comprises an effective amount of a prostaglandin analogue, such as travoprost, latanoprost, bimatoprost and tafluprost, in particular travoprost (0.1-0.6 % in mass relative to the microsphere), at least one hydrophilic degradable microsphere as defined above, and a pharmaceutically acceptable carrier for administration by injection.
  • a prostaglandin analogue such as travoprost, latanoprost, bimatoprost and tafluprost, in particular travoprost (0.1-0.6 % in mass relative to the microsphere)
  • at least one hydrophilic degradable microsphere as defined above
  • a pharmaceutically acceptable carrier for administration by injection for administration by injection.
  • prostaglandin analogues in particular the travoprost, and the hydrophilic degradable microsphere are as defined above.
  • the pharmaceutically acceptable carrier is intended for administration of a the prostaglandin analogue, in particular the travoprost, by injection and is advantageously selected in the group consisting in water for injection, saline, glucose, starch, hydrogel, polyvinylpyrrolidone, polysaccharide, hyaluronic acid ester, contrast agent and plasma.
  • the formulations may be administered by subconjunctival injection.
  • the formulations of hydrophilic degradable microspheres are syringable, the microsphere size and distribution are shown in Figure 5 for example. This enables the administration in a needle that is from between 21 and 34 gauge.
  • composition of the invention can also contain a buffering agent, a preservative, a gelling agent, a surfactant, or mixtures thereof.
  • the pharmaceutically acceptable carrier is saline or water for injection.
  • composition of the invention allows the sustained release of the prostaglandin analogue, in particular travoprost, over a period ranging from a few hours to a few months.
  • composition of the invention allows the sustained-release of the prostaglandin analogue, in particular travoprost, for at least 4 weeks without burst, in particular between 4 weeks and 6 months, more particularly between 4 weeks and 3 months.
  • composition of the invention allows the control of the sustained-release as defined above, for example by modulating the nature and the contents of monomers a), b) and/or c) and the amount of loaded the prostaglandin analogue, in particular travoprost.
  • the invention also relates to the composition as defined above, for use for preventing and/or treating ocular hypertension or glaucoma.
  • the invention also relates to a method for preventing and/or treating ocular hypertension or glaucoma, comprising administering to a subject in need thereof an effective amount of the composition as defined above.
  • the invention also relates to the use of the composition as defined above for the manufacturing of a drug for preventing and/or treating ocular hypertension or glaucoma.
  • the travoprost may be loaded extemporaneously on dry and sterile microsphere.
  • the invention thus also relates to a pharmaceutical kit comprising:
  • injection device means any device for parenteral administration.
  • the injection device is one or more syringes, which may be pre-filled, and/or one or more catheters or microcatheters.
  • the invention also relates to the hydrophilic degradable microsphere as defined above for use for the delivery, advantageously the sustained-delivery, of an effective amount of travoprost to a subject in need thereof.
  • the sustained delivery of travoprost is over a period ranging from a few weeks to a few months without burst, advantageously for at least 4 weeks, in particular between 4 weeks and 6 months, more particularly between 4 weeks and 3 months.
  • composition of the invention allows the sustained release of travoprost over a period ranging from a few hours to a few months.
  • composition of the invention allows the sustained-release of travoprost for at least 4 weeks without burst, in particular between 4 weeks and 6 months, more particularly between 4 weeks and 3 months.
  • Table 1 The starting components and their contents are summarized in Table 1. Table 1 also summarizes the main parameters.
  • the organic phase is prepared in an Erlenmeyer. Briefly, toluene (36.9 g) and 2,2'-azobis(2-methylpropionitrile) (AIBN) (0.28% weight/ organic phase weight) are weighted. AIBN is introduced in another vial and solubilized in a volume fraction ( ⁇ 30%) of the weighted toluene.
  • degradable crosslinker is weighted in an Erlenmeyer.
  • Mn 300 g/mol
  • MDO 2-Methylene-1,3-dioxepane
  • Hexanethiol (3 % mol /mol of PEGma) is added to the Erlenmeyer.
  • the AIBN solution in toluene is added to the erlenmeyer containing monomers.
  • the organic phase has to be clear (monomer and initiator should be totally solubilized) without any aggregates before introduction into the aqueous phase.
  • the organic phase is poured into the aqueous phase at 50°C. Thereupon, stirring (240 rpm) is applied by using an impeller. After 4 minutes, the temperature is raised up to 80°C. After 8 hours, the stirring is stopped and microspheres were collected by filtration on a 40 ⁇ m sieve and washed extensively with acetone and water. Microspheres were then sieved with decreasing sizes of sieves (125, 100, 50 ⁇ m).
  • MS in the size range 50-100 ⁇ m were collected for drug loading trials.
  • Example 2 Loading of microspheres according to example 1 with travoprost (preloading after MS synthesis)
  • microspheres obtained in example 1 size range 50-100 ⁇ m
  • water 500 ⁇ L or 1 mL
  • 500 ⁇ L or 1 mL 500 ⁇ L or 1 mL
  • travoprost solution Sigma, PHR 1622-3mL lot LRAA5292 (0.499 ⁇ g/mL in water/acetonitrile (70/30%)
  • the loading step was done at room temperature for 1 h under stirring on a tube rotator ( ⁇ 30 rpm). Then, the supernatants were removed for the measurement of unbound travoprost by fluorimetry ( ⁇ ex 220 nm, ⁇ Em 310 nm). The amount of travoprost in supernatant was obtained by extrapolation from a standard curve (0.6 to 20 ⁇ g/mL), and the loaded dose was calculated by subtraction.
  • the pellets were washed with 2 mL of glucose (2.5 % in water). Then, the microsphere pellets were frozen-dried before e-beam sterilization (15 kilograys).
  • Table 2 summarizes travoprost loading for each MS formulation tested. Table 2.
  • Travoprost loading in the microspheres according to example 2 Test number Travoprost loading (mg/ml) for 0.5 mL of travoprost solution (% of loading efficacy) Travoprost loading (mg/ml) for 1 mL of travoprost solution (% of loading efficacy) MS1 0.93 ⁇ 0.01 (93 %) 1.79 ⁇ 0.004 (90%) MS2 0.98 ⁇ 0.001 (99 %) 1.95 ⁇ 0.001 (97 %) MS3 0.94 ⁇ 0.004 (95 %) 1.86 ⁇ 0.0028 (93 %) MS4 0.98 ⁇ 0.0003 (99 %) 1.95 ⁇ 0.009 (98 %) MS5 0.98 ⁇ 0.003 (99 %) 1.96 ⁇ 0.001 (98 %) 1.96 ⁇ 0.001 (98 %) 1.97 ⁇ 0.003 (98 %).
  • Example 3 Extemporaneous loading of travoprost on sterile microspheres according to example 1
  • a suspension of 250 ⁇ L of microspheres in 15 mL of a solution containing 2.5 % (w/v) of mannitol was prepared. After homogenization, the pellet of microspheres was recovered, frozen-dried and sterilized by e-beam radiation (15-25 kilograys).
  • the loading step was done at room temperature for 5 min under stirring on a tube rotator ( ⁇ 30 rpm). Then, the supernatants were removed for the measurement of unbound travoprost by fluorimetry ( ⁇ ex 220 nm, ⁇ Em 310 nm). The amount of travoprost was obtained by extrapolation from a standard curve (0.6 to 20 ⁇ g/mL).
  • Table 3 summarizes extemporaneous travoprost loading on dry and sterile MS of different formulations tested. Table 3. Travoprost loading in the microspheres according to example 3 Test number Travoprost loading (mg/ml) for 0.5 mL of travoprost solution (% of loading efficacy) MS1 0.9 ⁇ 0.011 (90%) MS5 1.98 ⁇ 0.14 (99 %)
  • Example 4 Study of the in vitro release of travoprost from loading microsphere according to example 2
  • the swelling step of microspheres was performed for 10 min in 10 mL of 0.9 % NaCl saline solution. After the removal of saline, 50 mL of PBS (Sigma P-5368; 10 mM phosphate buffered saline; NaCl 0,136 M; KCl 0,0027 M; pH 7.4 at 25°C) were added. Drug elution occurred at 37°C under shaking (150 rpm), the tubes were placed horizontally in the oven. Samples (1 mL) were withdrawn after 2h, 24 h and every 3 or 4 days for one month. At each sampling time, the medium was completely renewed with fresh PBS.
  • PBS Sigma P-5368
  • 10 mM phosphate buffered saline NaCl 0,136 M
  • KCl 0,0027 M pH 7.4 at 25°C
  • the amounts of free travoprost in saline and PBS supernatants were determined by RP-HPLC at 222 nm on a C 18 column (46 x 150 mm) using a mobile phase made of acetonitrile/water containing 0.1 % TFA (60:40, v/v) at a flow rate of 1 mL/min in the isocratic mode at 25°C.
  • Table 4 summarizes the travoprost elution during the swelling in saline of dry travoprost-loaded MS. and the further travoprost elution in PBS (in sink condition).
  • the travoprost loading was 1 mg/mL.
  • Table 5 summarizes the travoprost elution during the swelling in saline of dry travoprost-loaded MS. and the further travoprost elution in PBS (in sink condition).
  • the travoprost loading was 2 mg/mL.
  • Table 5 Travoprost elution after swelling of MS loaded at 2 mg/mL and after their subsequent transfer in PBS according to example 4.
  • Figure 2 represents the effect of MS composition on travoprost release during the swelling of dry microspheres in saline during 10 minutes at room temperature.
  • Figure 3 represents the elution of travoprost for MS3-5-6 for a travoprost loading of 1 mg/mL
  • Figure 4 represent the elution of travoprost for MS5-6 for a travoprost loading of 2 mg/mL
  • Example 5 Size distribution of sterile hydrophilic microspheres (MS1 ⁇ t MS3) after swelling in saline

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Emergency Medicine (AREA)
  • Dermatology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
EP20305777.3A 2020-07-07 2020-07-07 Microsphères dégradables hydrophiles pour administration de travoprost Withdrawn EP3936113A1 (fr)

Priority Applications (6)

Application Number Priority Date Filing Date Title
EP20305777.3A EP3936113A1 (fr) 2020-07-07 2020-07-07 Microsphères dégradables hydrophiles pour administration de travoprost
US18/003,180 US20230241017A1 (en) 2020-07-07 2021-07-07 Hydrophilic Degradable Microsphere for Delivering Travoprost
JP2023525117A JP2023533391A (ja) 2020-07-07 2021-07-07 トラボプロストを送達するための親水性分解性マイクロスフェア
PCT/EP2021/068911 WO2022008625A1 (fr) 2020-07-07 2021-07-07 Microsphère dégradable hydrophile pour l'administration de travoprost
AU2021304877A AU2021304877A1 (en) 2020-07-07 2021-07-07 Hydrophilic degradable microsphere for delivering travoprost
EP21742107.2A EP4178533A1 (fr) 2020-07-07 2021-07-07 Microsphère dégradable hydrophile pour l'administration de travoprost

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP20305777.3A EP3936113A1 (fr) 2020-07-07 2020-07-07 Microsphères dégradables hydrophiles pour administration de travoprost

Publications (1)

Publication Number Publication Date
EP3936113A1 true EP3936113A1 (fr) 2022-01-12

Family

ID=71944038

Family Applications (2)

Application Number Title Priority Date Filing Date
EP20305777.3A Withdrawn EP3936113A1 (fr) 2020-07-07 2020-07-07 Microsphères dégradables hydrophiles pour administration de travoprost
EP21742107.2A Withdrawn EP4178533A1 (fr) 2020-07-07 2021-07-07 Microsphère dégradable hydrophile pour l'administration de travoprost

Family Applications After (1)

Application Number Title Priority Date Filing Date
EP21742107.2A Withdrawn EP4178533A1 (fr) 2020-07-07 2021-07-07 Microsphère dégradable hydrophile pour l'administration de travoprost

Country Status (5)

Country Link
US (1) US20230241017A1 (fr)
EP (2) EP3936113A1 (fr)
JP (1) JP2023533391A (fr)
AU (1) AU2021304877A1 (fr)
WO (1) WO2022008625A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116693823A (zh) * 2023-04-25 2023-09-05 广州工程技术职业学院 可降解聚合物纳米凝胶微球及其制备方法和应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060182781A1 (en) * 2004-04-30 2006-08-17 Allergan, Inc. Methods for treating ocular conditions with cyclic lipid contraining microparticles
WO2012120138A1 (fr) * 2011-03-09 2012-09-13 Occlugel Polymère biorésorbable gonflable implantable

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7799336B2 (en) * 2004-04-30 2010-09-21 Allergan, Inc. Hypotensive lipid-containing biodegradable intraocular implants and related methods
CN105682645B (zh) * 2013-10-31 2019-09-06 阿勒根公司 含前列腺酰胺的眼内植入物及其使用方法
MX2016007345A (es) * 2013-12-06 2016-12-09 Envisia Therapeutics Inc Implante intracameral para el tratamiento de una condicion ocular.

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060182781A1 (en) * 2004-04-30 2006-08-17 Allergan, Inc. Methods for treating ocular conditions with cyclic lipid contraining microparticles
WO2012120138A1 (fr) * 2011-03-09 2012-09-13 Occlugel Polymère biorésorbable gonflable implantable

Non-Patent Citations (20)

* Cited by examiner, † Cited by third party
Title
BENZON ET AL., ANESTHESIOLOGY, vol. 106, 2007, pages 331 - 8
BROWN ET AL., CAN J OPHTHALMOL., vol. 19, 1984, pages 2 - 5
CARBONNIERE ET AL., J FR OPHTALMOL., vol. 40, 2017, pages 177 - 86
FEDORCHAK ET AL., EXP EYE RES., vol. 125, August 2014 (2014-08-01), pages 210 - 6
GANDOLFI ET AL., ARCH OPHTHALMOL., vol. 113, 1995, pages 582 - 5
GIARMOUKAKIS ET AL., EXP EYE RES., vol. 112, 2013, pages 29 - 36
HUANG ET AL., J OCUL PHARMACOL THER., vol. 21, 2005, pages 445 - 53
LAVIK ET AL., J OCUL PHARMACOL THER., vol. 32, 2016, pages 642 - 49
LI ET AL., MEDICINE, vol. 97, 2018, pages 17
MARTINEZ-DE-LA-CASA ET AL., EYE, vol. 26, 2012, pages 972 - 75
NATARAJAN ET AL., ACS NANO., vol. 8, 2014, pages 419 - 29
NG ET AL., DRUG DELIV. AND TRANSL. RES., vol. 5, 2015, pages 469 - 79
NORDSTROM ET AL., AM J OPHTHALMOL., vol. 140, 2005, pages 598 - 606
QUEK ET AL., ARCH OPHTHALMOL., vol. 129, 2011, pages 643 - 8
SALAMA ET AL., AAPS PHARMSCITECH., vol. 18, 2017, pages 2517 - 28
SEN ET AL., BR J OPHTHALMOL., vol. 89, 2005, pages 917 - 8
SHU ET AL., EYE AND VISION., vol. 6, 2019, pages 15
SONG ET AL., J GLAUCOMA., vol. 22, 2013, pages 190 - 4
SUBRIZI ET AL., DRUG DISCOVERY TODAY, vol. 24, 2019, pages 1446 - 57
ZHANG ET AL., INVEST OPHTHALMOL VIS SCI., vol. 52, 2011, pages 7787 - 91

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116693823A (zh) * 2023-04-25 2023-09-05 广州工程技术职业学院 可降解聚合物纳米凝胶微球及其制备方法和应用
CN116693823B (zh) * 2023-04-25 2024-02-13 广州工程技术职业学院 可降解聚合物纳米凝胶微球及其制备方法和应用

Also Published As

Publication number Publication date
EP4178533A1 (fr) 2023-05-17
JP2023533391A (ja) 2023-08-02
AU2021304877A1 (en) 2023-01-19
WO2022008625A1 (fr) 2022-01-13
US20230241017A1 (en) 2023-08-03

Similar Documents

Publication Publication Date Title
Allyn et al. Considerations for polymers used in ocular drug delivery
Chang et al. Hydrogels for sustained delivery of biologics to the back of the eye
EP0212959B1 (fr) Formulation à effet retard contenant un polymère à base d'amino-acides et un solvant alkylé inférieur en C1-C4 polaire
EP3413933B1 (fr) Nanocolle d'hydrogel de polymère bioadhésif dendrimère et son utilisation
JP6570513B2 (ja) 持続的眼内放出のためのマイクロスフェア薬剤送達システム
Li et al. Flexible polymeric nanosized micelles for ophthalmic drug delivery: research progress in the last three years
JP2010519183A (ja) 生理溶液の溶出のためのタンパク質の沈殿を用いる重合
US9949928B2 (en) Biodegradable copolymers, systems including the copolymers, and methods of forming and using same
US20230140691A1 (en) Optically clear, in-situ forming biodegradable nano-carriers for ocular therapy, and methods using same
JP4309974B2 (ja) 眼科用製剤
Zou et al. A thermo-sensitive, injectable and biodegradable in situ hydrogel as a potential formulation for uveitis treatment
JP7355649B2 (ja) 薬物－ポリマーコンジュゲート
Fitzpatrick et al. Development of injectable, resorbable drug-releasing copolymer scaffolds for minimally invasive sustained ophthalmic therapeutics
Ow et al. Recent developments of temperature‐responsive polymers for ophthalmic applications
US10653783B2 (en) Sustained release of bioactive factors from zwitterionic hydrogels
EP3936113A1 (fr) Microsphères dégradables hydrophiles pour administration de travoprost
MXPA04012897A (es) Sistema de administracion de farmacos por difusion controlada de matriz de fluorosiloxano.
Sha et al. In situ gels: The next new frontier in ophthalmic drug delivery system
JP2023533774A (ja) ブプレノルフィンを送達するための親水性分解性マイクロスフェア
CN115919755A (zh) 一种低浓度水凝胶及其制备方法和应用
US8920841B2 (en) Biodegradable polymer system
Wang et al. Recent advances and future perspectives of long-acting ophthalmic preparations (LAOPs) in clinical applications
Al-Shohani Hydrogel formulations for ophthalmic delivery
EP4605017A1 (fr) Formulation antifibrotique pour traitement ophtalmique
Farooq et al. Current trends in novel ophthalmic drug delivery system: An overview

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN PUBLISHED

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

B565 Issuance of search results under rule 164(2) epc

Effective date: 20210217

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20220713